Fate Therapeutics (FATE)

$2.37 -0.06 (-2.47%)
Market Cap 291.17M
Revenue (ttm) 6.65M
Net Income (ttm) -136.32M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -2,049.92%
Debt to Equity Ratio 0.00
Volume 281,632
Avg Vol 3,141,118
Day's Range N/A - N/A
Shares Out 119.82M
Stochastic %K 43%
Beta 2.52
Analysts Sell
Price Target $5.74

Company Profile

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, FT839, to treat complex...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 875 1800
Address:
12278 Scripps Summit Drive, San Diego, United States
Baskinta1
Baskinta1 Aug. 31 at 12:59 PM
$FATE Interesting development: Johnson & Johnson disclosed a new position of about 3.38 million FATE shares, worth roughly $9.1M at the reported valuation. * FATE also has FT839, with FDA clearance of its IND and a Phase 1/2 autoimmune/hematologic trial expected to begin enrolling in 2H 2026.
1 · Reply
radonco
radonco Aug. 30 at 7:02 PM
$FATE 223 $5 calls bought last week expiring Nov 20…maybe something brewing
1 · Reply
Chico1234
Chico1234 Aug. 29 at 4:04 PM
$FATE I’m not betting everything on one good headline
1 · Reply
Rocketman808
Rocketman808 Aug. 28 at 3:21 PM
$FATE Jake, whens the buyout?
1 · Reply
StockDaddy68
StockDaddy68 Aug. 28 at 12:21 PM
$FATE Good Morning Everyone! Let's send this rocket into space today!
0 · Reply
StockDaddy68
StockDaddy68 Aug. 27 at 2:55 PM
$FATE Uh oh @Jake140 is interested in this one y'all it MUST be a 10 Bagger!!!
1 · Reply
StockDaddy68
StockDaddy68 Aug. 27 at 10:47 AM
$FATE Good Morning Everyone still Long and Strong!
0 · Reply
Edgebell
Edgebell Aug. 26 at 7:52 PM
$TGTX $MRNA $FATE While the broader market chopped around, our Edgebell system flagged a massive setup hiding in plain sight. Back at the end of June, we called out $XBI right as the technicals aligned with a surge in volume on the breakout. The Edgebell score indicators didn't stutter—they mapped out the momentum shift before the rest of the Street caught on. While everyone else is chasing noise, our favorite biotech plays remain locked in: $TGTX (TG Therapeutics) $MRNA (Moderna) $FATE (Fate Therapeutics) We aren’t treating biotech as a short-term trade. This sector is setting up to be a top structural leader heading straight into 2027. #Edgebell #Biotech #XBI #Trading #SwingTrading #StockMarket #TechnicalAnalysis #TGTX #MRNA #FATE #Investing #MarketSignals
0 · Reply
Jake140
Jake140 Aug. 26 at 6:21 PM
$FATE Afternoon All! Still here...still bullish on $FATE!
0 · Reply
StockDaddy68
StockDaddy68 Aug. 26 at 1:36 PM
$FATE Good Morning Everyone!
0 · Reply
Latest News on FATE
Fate Therapeutics reports Q2 EPS (25c), consensus (26c)

2026-08-17T07:43:48.000Z - 14 days ago

Fate Therapeutics reports Q2 EPS (25c), consensus (26c)

Fate Therapeutics price target raised to $3.50 from $2.50 at Wells Fargo

2026-08-16T13:49:33.000Z - 15 days ago

Fate Therapeutics price target raised to $3.50 from $2.50 at Wells Fargo

Fate Therapeutics intiates first patient in RECLAIM-LN trial

2026-08-16T13:40:14.000Z - 15 days ago

Fate Therapeutics intiates first patient in RECLAIM-LN trial

Fate Therapeutics price target raised to $8 from $6 at Piper Sandler

2026-08-16T13:27:27.000Z - 15 days ago

Fate Therapeutics price target raised to $8 from $6 at Piper Sandler

Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Treatment of Lupus Nephritis

Aug 14, 2026, 7:00 AM EDT - 17 days ago

Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Treatment of Lupus Nephritis

Fate Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates

Aug 13, 2026, 8:30 AM EDT - 18 days ago

Fate Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates

Fate Therapeutics Quarterly report: Q2 2026

Aug 13, 2026, 7:00 AM EDT - 18 days ago

Fate Therapeutics Quarterly report: Q2 2026

Fate Therapeutics Earnings release: Q2 2026

Aug 13, 2026, 7:00 AM EDT - 18 days ago

Fate Therapeutics Earnings release: Q2 2026

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Aug 3, 2026, 4:05 PM EDT - 27 days ago

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Fate Therapeutics announces FDA clearance of FT839 IND application

2026-07-09T13:15:20.000Z - 7 weeks ago

Fate Therapeutics announces FDA clearance of FT839 IND application

Fate Therapeutics Receives FDA Clearance of Investigational New Drug Application for FT839 Product Candidate

Jul 9, 2026, 8:30 AM EDT - 7 weeks ago

Fate Therapeutics Receives FDA Clearance of Investigational New Drug Application for FT839 Product Candidate

Fate Therapeutics to Present Preliminary Clinical Data of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Sclerosis at the ISSCR 2026 Annual Meeting

Jul 6, 2026, 8:30 AM EDT - 2 months ago

Fate Therapeutics to Present Preliminary Clinical Data of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Sclerosis at the ISSCR 2026 Annual Meeting

Fate Therapeutics to Participate in Upcoming Third Quarter 2026 Conferences

Jul 1, 2026, 4:05 PM EDT - 2 months ago

Fate Therapeutics to Participate in Upcoming Third Quarter 2026 Conferences

Fate Therapeutics Appoints Laura Hamill to Board of Directors

Jun 15, 2026, 8:30 AM EDT - 2 months ago

Fate Therapeutics Appoints Laura Hamill to Board of Directors

Fate Therapeutics Showcases Data from FT819 and FT839 Programs at the European Congress of Rheumatology Annual Meeting

Jun 4, 2026, 8:30 AM EDT - 3 months ago

Fate Therapeutics Showcases Data from FT819 and FT839 Programs at the European Congress of Rheumatology Annual Meeting

Fate Therapeutics management to meet with Piper Sandler

2026-06-03T20:55:38.000Z - 3 months ago

Fate Therapeutics management to meet with Piper Sandler

Fate Therapeutics Slides: Corporate presentation

Jun 3, 2026, 7:00 AM EDT - 3 months ago

Fate Therapeutics Slides: Corporate presentation

Fate Therapeutics Showcases Clinical Data for FT836 at the American Society of Cancer Oncology Annual Meeting

Jun 1, 2026, 8:30 AM EDT - 3 months ago

Fate Therapeutics Showcases Clinical Data for FT836 at the American Society of Cancer Oncology Annual Meeting

Fate Therapeutics price target raised to $2.20 from $2 at BofA

2026-05-22T11:55:08.000Z - 3 months ago

Fate Therapeutics price target raised to $2.20 from $2 at BofA

Fate Therapeutics Announces Presentations at 2026 ASCO and EULAR Annual Meetings Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune Diseases

May 21, 2026, 8:30 AM EDT - 3 months ago

Fate Therapeutics Announces Presentations at 2026 ASCO and EULAR Annual Meetings Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune Diseases

Fate Therapeutics assumed with a Buy at Jefferies

2026-05-19T19:15:09.000Z - 3 months ago

Fate Therapeutics assumed with a Buy at Jefferies

Fate Therapeutics reports Q1 EPS (26c), consensus (28c)

2026-05-13T15:28:57.000Z - 3 months ago

Fate Therapeutics reports Q1 EPS (26c), consensus (28c)

Fate Therapeutics Reports First Quarter 2026 Financial Results and Business Updates

May 13, 2026, 8:30 AM EDT - 3 months ago

Fate Therapeutics Reports First Quarter 2026 Financial Results and Business Updates

Fate Therapeutics Earnings release: Q1 2026

May 13, 2026, 8:30 AM EDT - 3 months ago

Fate Therapeutics Earnings release: Q1 2026

Fate Therapeutics Quarterly report: Q1 2026

May 13, 2026, 8:30 AM EDT - 3 months ago

Fate Therapeutics Quarterly report: Q1 2026

Fate Therapeutics Showcases FT819 Clinical Activity in SLE without the use of Conditioning Chemotherapy at the 2026 ASGCT Annual Meeting

May 11, 2026, 8:30 AM EDT - 4 months ago

Fate Therapeutics Showcases FT819 Clinical Activity in SLE without the use of Conditioning Chemotherapy at the 2026 ASGCT Annual Meeting

Fate Therapeutics Selected for U.S. FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program to Support Manufacturing Readiness of FT819

May 5, 2026, 8:30 AM EDT - 4 months ago

Fate Therapeutics Selected for U.S. FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program to Support Manufacturing Readiness of FT819

Fate Therapeutics Announces Three Presentations at the 2026 ASGCT Annual Meeting Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune Diseases

May 4, 2026, 9:00 AM EDT - 4 months ago

Fate Therapeutics Announces Three Presentations at the 2026 ASGCT Annual Meeting Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune Diseases

Fate Therapeutics price target raised to $7 from $5 at H.C. Wainwright

2026-05-04T10:17:06.000Z - 4 months ago

Fate Therapeutics price target raised to $7 from $5 at H.C. Wainwright

Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

May 1, 2026, 4:05 PM EDT - 4 months ago

Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

Fate Therapeutics Announces Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Lupus Erythematosus (SLE) at the CCR – East 2026 Meeting

Apr 30, 2026, 9:00 AM EDT - 4 months ago

Fate Therapeutics Announces Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Lupus Erythematosus (SLE) at the CCR – East 2026 Meeting

SLE

Fate Therapeutics Proxy statement: Proxy filing

Apr 24, 2026, 8:00 AM EDT - 4 months ago

Fate Therapeutics Proxy statement: Proxy filing

Fate Therapeutics Proxy statement: Proxy filing

Apr 24, 2026, 8:00 AM EDT - 4 months ago

Fate Therapeutics Proxy statement: Proxy filing

Fate Therapeutics announces data presentation of FT839

2026-04-16T13:53:30.000Z - 4 months ago

Fate Therapeutics announces data presentation of FT839

Fate Therapeutics Transcript: 25th Annual Needham Virtual Healthcare Conference

Apr 14, 2026, 3:45 PM EDT - 4 months ago

Fate Therapeutics Transcript: 25th Annual Needham Virtual Healthcare Conference

Fate Therapeutics Transcript: Leerink Global Healthcare Conference 2026

Mar 9, 2026, 9:20 AM EDT - 6 months ago

Fate Therapeutics Transcript: Leerink Global Healthcare Conference 2026

Fate Therapeutics to Participate in Leerink Partners 2026 Global Healthcare Conference

Mar 3, 2026, 4:05 PM EST - 6 months ago

Fate Therapeutics to Participate in Leerink Partners 2026 Global Healthcare Conference

Fate Therapeutics reports Q4 EPS (77c), consensus (27c)

2026-02-26T14:07:37.000Z - 6 months ago

Fate Therapeutics reports Q4 EPS (77c), consensus (27c)

Fate Therapeutics Earnings release: Q4 2025

Feb 26, 2026, 7:00 AM EST - 6 months ago

Fate Therapeutics Earnings release: Q4 2025

Fate Therapeutics Annual report: Q4 2025

Feb 26, 2026, 7:00 AM EST - 6 months ago

Fate Therapeutics Annual report: Q4 2025

Fate Therapeutics Annual report: Q4 2025

Feb 26, 2026, 7:00 AM EST - 6 months ago

Fate Therapeutics Annual report: Q4 2025

Fate Therapeutics Slides: Corporate presentation

Feb 26, 2026, 7:00 AM EST - 6 months ago

Fate Therapeutics Slides: Corporate presentation

IPSC-derived NK Cells Clinical Trial Pipeline Gains Momentum: 12+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

Feb 16, 2026, 1:00 PM EST - 7 months ago

IPSC-derived NK Cells Clinical Trial Pipeline Gains Momentum: 12+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

IPSC

Fate Therapeutics presents updated Phase 1 data of FT819

2025-12-08T13:21:05.000Z - 9 months ago

Fate Therapeutics presents updated Phase 1 data of FT819

Fate Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference

Dec 2, 2025, 9:00 AM EST - 9 months ago

Fate Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference

Fate Therapeutics to Present at Piper Sandler 37th Annual Healthcare Conference

Nov 25, 2025, 8:00 AM EST - 9 months ago

Fate Therapeutics to Present at Piper Sandler 37th Annual Healthcare Conference

Fate Therapeutics reports Q3 EPS (27c), consensus (28c)

2025-11-13T13:35:50.000Z - 10 months ago

Fate Therapeutics reports Q3 EPS (27c), consensus (28c)

Fate Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates

Nov 13, 2025, 8:30 AM EST - 10 months ago

Fate Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates

Fate Therapeutics Earnings release: Q3 2025

Nov 13, 2025, 8:30 AM EST - 10 months ago

Fate Therapeutics Earnings release: Q3 2025

Fate Therapeutics Quarterly report: Q3 2025

Nov 13, 2025, 8:30 AM EST - 10 months ago

Fate Therapeutics Quarterly report: Q3 2025

Fate Therapeutics upgraded to Buy from Neutral at H.C. Wainwright

2025-10-31T10:15:39.000Z - 10 months ago

Fate Therapeutics upgraded to Buy from Neutral at H.C. Wainwright

Wedbush upgrades Fate Therapeutics to Outperform, raises target to $7

2025-10-27T13:45:07.000Z - 11 months ago

Wedbush upgrades Fate Therapeutics to Outperform, raises target to $7

Fate Therapeutics upgraded to Outperform from Neutral at Wedbush

2025-10-27T11:05:46.000Z - 11 months ago

Fate Therapeutics upgraded to Outperform from Neutral at Wedbush

Fate Therapeutics Presents New Clinical Data at ACR Convergence 2025 Demonstrating Immune Remodeling and Durable Responses in Patients with Systemic Lupus Erythematosus Treated with FT819 Off-the-Shelf CAR T-Cell Therapy

Oct 26, 2025, 11:30 AM EDT - 11 months ago

Fate Therapeutics Presents New Clinical Data at ACR Convergence 2025 Demonstrating Immune Remodeling and Durable Responses in Patients with Systemic Lupus Erythematosus Treated with FT819 Off-the-Shelf CAR T-Cell Therapy

Fate Therapeutics appoints Adawi as CFO

2025-10-14T12:15:56.000Z - 11 months ago

Fate Therapeutics appoints Adawi as CFO

Fate Therapeutics Transcript: Cantor Global Healthcare Conference 2025

Sep 4, 2025, 10:55 AM EDT - 1 year ago

Fate Therapeutics Transcript: Cantor Global Healthcare Conference 2025

Fate Therapeutics price target lowered to $2.50 from $4 at Wells Fargo

2025-08-13T10:20:32.000Z - 1 year ago

Fate Therapeutics price target lowered to $2.50 from $4 at Wells Fargo

Fate Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates

Aug 12, 2025, 4:01 PM EDT - 1 year ago

Fate Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates

Fate Therapeutics Earnings release: Q2 2025

Aug 12, 2025, 7:00 AM EDT - 1 year ago

Fate Therapeutics Earnings release: Q2 2025

Fate Therapeutics Quarterly report: Q2 2025

Aug 12, 2025, 7:00 AM EDT - 1 year ago

Fate Therapeutics Quarterly report: Q2 2025

Fate Therapeutics Announces Updated Clinical Data for FT819 Off-the-shelf CAR T-cell Product Candidate Demonstrating Durability of Drug-free Remission for Severe Lupus Nephritis at EULAR 2025 Congress

Jun 11, 2025, 9:00 AM EDT - 1 year ago

Fate Therapeutics Announces Updated Clinical Data for FT819 Off-the-shelf CAR T-cell Product Candidate Demonstrating Durability of Drug-free Remission for Severe Lupus Nephritis at EULAR 2025 Congress

Fate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors

May 30, 2025, 4:30 PM EDT - 1 year ago

Fate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors

Fate Therapeutics Announces Phase 1 Data Presentation of FT819 Off-the-Shelf CAR T-cell Product Candidate for SLE at EULAR 2025 Congress

May 28, 2025, 5:54 PM EDT - 1 year ago

Fate Therapeutics Announces Phase 1 Data Presentation of FT819 Off-the-Shelf CAR T-cell Product Candidate for SLE at EULAR 2025 Congress

Fate Therapeutics Reports First Quarter 2025 Financial Results and Business Updates

May 13, 2025, 4:01 PM EDT - 1 year ago

Fate Therapeutics Reports First Quarter 2025 Financial Results and Business Updates

Fate Therapeutics Quarterly report: Q1 2025

May 13, 2025, 4:00 PM EDT - 1 year ago

Fate Therapeutics Quarterly report: Q1 2025

Fate Therapeutics Earnings release: Q1 2025

May 13, 2025, 4:00 PM EDT - 1 year ago

Fate Therapeutics Earnings release: Q1 2025

Fate Therapeutics Announces Five Presentations on Off-the-Shelf CAR T-cell Product Platform at ASGCT Annual Meeting

Apr 29, 2025, 9:25 AM EDT - 1 year ago

Fate Therapeutics Announces Five Presentations on Off-the-Shelf CAR T-cell Product Platform at ASGCT Annual Meeting

Fate Therapeutics Proxy statement: Proxy Filing

Apr 17, 2025, 8:00 AM EDT - 1 year ago

Fate Therapeutics Proxy statement: Proxy Filing

Fate Therapeutics Proxy statement: Proxy Filing

Apr 17, 2025, 8:00 AM EDT - 1 year ago

Fate Therapeutics Proxy statement: Proxy Filing

Fate Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for FT819 to Treat Moderate to Severe Systemic Lupus Erythematosus (SLE)

Apr 14, 2025, 8:00 AM EDT - 1 year ago

Fate Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for FT819 to Treat Moderate to Severe Systemic Lupus Erythematosus (SLE)

Fate Therapeutics Proxy statement: Proxy Filing

Apr 7, 2025, 8:00 AM EDT - 1 year ago

Fate Therapeutics Proxy statement: Proxy Filing

Fate Therapeutics Transcript: Leerink Global Healthcare Conference 2025

Mar 12, 2025, 11:20 AM EDT - 1 year ago

Fate Therapeutics Transcript: Leerink Global Healthcare Conference 2025

Fate Therapeutics Transcript: Barclays 27th Annual Global Healthcare Conference

Mar 11, 2025, 8:30 AM EDT - 1 year ago

Fate Therapeutics Transcript: Barclays 27th Annual Global Healthcare Conference

Fate Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates

Mar 5, 2025, 4:01 PM EST - 1 year ago

Fate Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates

Fate Therapeutics Annual report: Q4 2024

Mar 5, 2025, 4:00 PM EST - 1 year ago

Fate Therapeutics Annual report: Q4 2024

Fate Therapeutics Earnings release: Q4 2024

Mar 5, 2025, 4:00 PM EST - 1 year ago

Fate Therapeutics Earnings release: Q4 2024

Fate Therapeutics Transcript: TD Cowen 45th Annual Healthcare Conference

Mar 3, 2025, 11:50 AM EST - 1 year ago

Fate Therapeutics Transcript: TD Cowen 45th Annual Healthcare Conference

Fate Therapeutics to Present at Upcoming Investor Conferences

Feb 14, 2025, 4:01 PM EST - 1 year ago

Fate Therapeutics to Present at Upcoming Investor Conferences

Fate Therapeutics Slides: Corporate Presentation

Feb 7, 2025, 7:00 AM EST - 1 year ago

Fate Therapeutics Slides: Corporate Presentation

Fate Therapeutics Presents New Phase 1 Clinical Data of FT819 Off-the-shelf, CAR T-cell Product Candidate for Systemic Lupus Erythematosus

Dec 9, 2024, 4:01 PM EST - 1 year ago

Fate Therapeutics Presents New Phase 1 Clinical Data of FT819 Off-the-shelf, CAR T-cell Product Candidate for Systemic Lupus Erythematosus

Fate Therapeutics Transcript: Piper Sandler 36th Annual Healthcare Conference

Dec 4, 2024, 3:00 PM EST - 1 year ago

Fate Therapeutics Transcript: Piper Sandler 36th Annual Healthcare Conference

Fate Therapeutics Transcript: Citi's 2024 Global Healthcare Conference

Dec 3, 2024, 2:30 PM EST - 1 year ago

Fate Therapeutics Transcript: Citi's 2024 Global Healthcare Conference

Fate Therapeutics Announces Leadership Transition

Nov 29, 2024, 1:05 PM EST - 1 year ago

Fate Therapeutics Announces Leadership Transition

Fate Therapeutics to Present at Upcoming December Investor Conferences

Nov 26, 2024, 4:01 PM EST - 1 year ago

Fate Therapeutics to Present at Upcoming December Investor Conferences

Fate Therapeutics Presents 6-Month Follow-up Data on First Patient Treated in Phase 1 Autoimmunity Study with Fludarabine-free Conditioning and FT819 Off-the-shelf, 1XX CAR T-cell Product Candidate at ACR Convergence

Nov 18, 2024, 8:05 AM EST - 1 year ago

Fate Therapeutics Presents 6-Month Follow-up Data on First Patient Treated in Phase 1 Autoimmunity Study with Fludarabine-free Conditioning and FT819 Off-the-shelf, 1XX CAR T-cell Product Candidate at ACR Convergence

Fate Therapeutics Reports Third Quarter 2024 Financial Results and Business Updates

Nov 12, 2024, 4:01 PM EST - 1 year ago

Fate Therapeutics Reports Third Quarter 2024 Financial Results and Business Updates

Fate Therapeutics Quarterly report: Q3 2024

Nov 12, 2024, 3:00 PM EST - 1 year ago

Fate Therapeutics Quarterly report: Q3 2024

Fate Therapeutics Earnings release: Q3 2024

Nov 12, 2024, 3:00 PM EST - 1 year ago

Fate Therapeutics Earnings release: Q3 2024

Fate Therapeutics Highlights Cancer-selective, HER2-Targeting Profile of FT825 / ONO-8250 CAR T-cell Product Candidate for Treatment of Advanced Solid Tumors at 2024 SITC Annual Meeting

Nov 9, 2024, 1:30 PM EST - 1 year ago

Fate Therapeutics Highlights Cancer-selective, HER2-Targeting Profile of FT825 / ONO-8250 CAR T-cell Product Candidate for Treatment of Advanced Solid Tumors at 2024 SITC Annual Meeting

Fate Therapeutics Presents Pan-tumor Targeting Preclinical Data for FT836 MICA/B-targeted CAR T-cell Product Candidate at 2024 SITC Annual Meeting

Nov 8, 2024, 4:01 PM EST - 1 year ago

Fate Therapeutics Presents Pan-tumor Targeting Preclinical Data for FT836 MICA/B-targeted CAR T-cell Product Candidate at 2024 SITC Annual Meeting

Fate Therapeutics Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Sep 19, 2024, 12:45 PM EDT - 2 years ago

Fate Therapeutics Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Fate Therapeutics to Present at 2024 Cantor Global Healthcare Conference

Sep 12, 2024, 4:01 PM EDT - 2 years ago

Fate Therapeutics to Present at 2024 Cantor Global Healthcare Conference

Fate Therapeutics Reports Second Quarter 2024 Financial Results and Business Updates

Aug 13, 2024, 4:05 PM EDT - 2 years ago

Fate Therapeutics Reports Second Quarter 2024 Financial Results and Business Updates

Fate Therapeutics Quarterly report: Q2 2024

Aug 13, 2024, 4:00 PM EDT - 2 years ago

Fate Therapeutics Quarterly report: Q2 2024

Fate Therapeutics Earnings release: Q2 2024

Aug 13, 2024, 4:00 PM EDT - 2 years ago

Fate Therapeutics Earnings release: Q2 2024

Fate Therapeutics Transcript: Jefferies 2024 Global Healthcare Conference

Jun 5, 2024, 3:00 PM EDT - 2 years ago

Fate Therapeutics Transcript: Jefferies 2024 Global Healthcare Conference

Fate Therapeutics to Present at 2024 Jefferies Global Healthcare Conference

May 29, 2024, 4:01 PM EDT - 2 years ago

Fate Therapeutics to Present at 2024 Jefferies Global Healthcare Conference

Fate Therapeutics Earnings Call Transcript: Q1 2024

May 9, 2024, 5:00 PM EDT - 2 years ago

Fate Therapeutics Earnings Call Transcript: Q1 2024

Fate Therapeutics Quarterly report: Q1 2024

May 9, 2024, 5:00 PM EDT - 2 years ago

Fate Therapeutics Quarterly report: Q1 2024

Fate Therapeutics Earnings release: Q1 2024

May 9, 2024, 5:00 PM EDT - 2 years ago

Fate Therapeutics Earnings release: Q1 2024

Fate Therapeutics Reports First Quarter 2024 Financial Results and Business Updates

May 9, 2024, 4:01 PM EDT - 2 years ago

Fate Therapeutics Reports First Quarter 2024 Financial Results and Business Updates

Fate Therapeutics Announces First Lupus Patient Treated in Phase 1 Autoimmunity Study of Off-the-shelf FT819 CAR T-cell Program

May 9, 2024, 8:30 AM EDT - 2 years ago

Fate Therapeutics Announces First Lupus Patient Treated in Phase 1 Autoimmunity Study of Off-the-shelf FT819 CAR T-cell Program

Fate Therapeutics Announces Presentation of FT522 Preclinical Data for Autoimmune Diseases in Late-breaking Abstract at ASGCT Annual Meeting

May 3, 2024, 4:30 PM EDT - 2 years ago

Fate Therapeutics Announces Presentation of FT522 Preclinical Data for Autoimmune Diseases in Late-breaking Abstract at ASGCT Annual Meeting

Fate Therapeutics Proxy statement: Proxy Filing

Apr 26, 2024, 8:00 AM EDT - 2 years ago

Fate Therapeutics Proxy statement: Proxy Filing

Fate Therapeutics Proxy statement: Proxy Filing

Apr 26, 2024, 8:00 AM EDT - 2 years ago

Fate Therapeutics Proxy statement: Proxy Filing

Fate Therapeutics Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual Meeting

Apr 22, 2024, 4:30 PM EDT - 2 years ago

Fate Therapeutics Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual Meeting

Fate Therapeutics Registration statement: Registration Filing

Apr 18, 2024, 8:00 AM EDT - 2 years ago

Fate Therapeutics Registration statement: Registration Filing

Fate Therapeutics Proxy statement: Proxy Filing

Apr 16, 2024, 8:00 AM EDT - 2 years ago

Fate Therapeutics Proxy statement: Proxy Filing

Fate Therapeutics Transcript: 23rd Annual Needham Virtual Healthcare Conference

Apr 10, 2024, 2:15 PM EDT - 2 years ago

Fate Therapeutics Transcript: 23rd Annual Needham Virtual Healthcare Conference

Fate Therapeutics Transcript: H.C. Wainwright 2ND Annual Cell Therapy Virtual Conference

Mar 26, 2024, 3:00 PM EDT - 2 years ago

Fate Therapeutics Transcript: H.C. Wainwright 2ND Annual Cell Therapy Virtual Conference

Fate Therapeutics Announces Pricing of $100 Million Underwritten Offering and Concurrent Private Placement

Mar 19, 2024, 8:44 AM EDT - 2 years ago

Fate Therapeutics Announces Pricing of $100 Million Underwritten Offering and Concurrent Private Placement

Fate Therapeutics Transcript: Barclays 26th Annual Global Healthcare Conference 2024

Mar 12, 2024, 11:15 AM EDT - 2 years ago

Fate Therapeutics Transcript: Barclays 26th Annual Global Healthcare Conference 2024

Fate Therapeutics Transcript: Leerink Partners Global Biopharma Conference 2024

Mar 11, 2024, 2:00 PM EDT - 2 years ago

Fate Therapeutics Transcript: Leerink Partners Global Biopharma Conference 2024

Fate Therapeutics Transcript: TD Cowen 44th Annual Health Care Conference 2024

Mar 6, 2024, 9:10 AM EST - 2 years ago

Fate Therapeutics Transcript: TD Cowen 44th Annual Health Care Conference 2024

Fate Therapeutics to Present at Upcoming March Investor Conferences

Mar 1, 2024, 8:00 AM EST - 2 years ago

Fate Therapeutics to Present at Upcoming March Investor Conferences

Fate Therapeutics Earnings Call Transcript: Q4 2023

Feb 26, 2024, 5:00 PM EST - 2 years ago

Fate Therapeutics Earnings Call Transcript: Q4 2023

Fate Therapeutics Annual report: Q4 2023

Feb 26, 2024, 5:00 PM EST - 2 years ago

Fate Therapeutics Annual report: Q4 2023

Fate Therapeutics Earnings release: Q4 2023

Feb 26, 2024, 5:00 PM EST - 2 years ago

Fate Therapeutics Earnings release: Q4 2023

Fate Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates

Feb 26, 2024, 4:01 PM EST - 2 years ago

Fate Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates

Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2023 Financial Results

Feb 15, 2024, 8:00 AM EST - 2 years ago

Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2023 Financial Results

Fate Therapeutics Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dec 13, 2023, 5:00 PM EST - 2 years ago

Fate Therapeutics Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Baskinta1
Baskinta1 Aug. 31 at 12:59 PM
$FATE Interesting development: Johnson & Johnson disclosed a new position of about 3.38 million FATE shares, worth roughly $9.1M at the reported valuation. * FATE also has FT839, with FDA clearance of its IND and a Phase 1/2 autoimmune/hematologic trial expected to begin enrolling in 2H 2026.
1 · Reply
radonco
radonco Aug. 30 at 7:02 PM
$FATE 223 $5 calls bought last week expiring Nov 20…maybe something brewing
1 · Reply
Chico1234
Chico1234 Aug. 29 at 4:04 PM
$FATE I’m not betting everything on one good headline
1 · Reply
Rocketman808
Rocketman808 Aug. 28 at 3:21 PM
$FATE Jake, whens the buyout?
1 · Reply
StockDaddy68
StockDaddy68 Aug. 28 at 12:21 PM
$FATE Good Morning Everyone! Let's send this rocket into space today!
0 · Reply
StockDaddy68
StockDaddy68 Aug. 27 at 2:55 PM
$FATE Uh oh @Jake140 is interested in this one y'all it MUST be a 10 Bagger!!!
1 · Reply
StockDaddy68
StockDaddy68 Aug. 27 at 10:47 AM
$FATE Good Morning Everyone still Long and Strong!
0 · Reply
Edgebell
Edgebell Aug. 26 at 7:52 PM
$TGTX $MRNA $FATE While the broader market chopped around, our Edgebell system flagged a massive setup hiding in plain sight. Back at the end of June, we called out $XBI right as the technicals aligned with a surge in volume on the breakout. The Edgebell score indicators didn't stutter—they mapped out the momentum shift before the rest of the Street caught on. While everyone else is chasing noise, our favorite biotech plays remain locked in: $TGTX (TG Therapeutics) $MRNA (Moderna) $FATE (Fate Therapeutics) We aren’t treating biotech as a short-term trade. This sector is setting up to be a top structural leader heading straight into 2027. #Edgebell #Biotech #XBI #Trading #SwingTrading #StockMarket #TechnicalAnalysis #TGTX #MRNA #FATE #Investing #MarketSignals
0 · Reply
Jake140
Jake140 Aug. 26 at 6:21 PM
$FATE Afternoon All! Still here...still bullish on $FATE!
0 · Reply
StockDaddy68
StockDaddy68 Aug. 26 at 1:36 PM
$FATE Good Morning Everyone!
0 · Reply
Nik7777
Nik7777 Aug. 26 at 8:47 AM
$FATE
0 · Reply
Gslam
Gslam Aug. 25 at 4:48 PM
$GALT and $FATE. Been following both for years. Enjoyed a previous FATE run a previous run years ago and banked. Both setting up. Been holding GALT for a while and hope this is it. GL.
1 · Reply
Rocketman808
Rocketman808 Aug. 24 at 6:26 PM
$FATE never should have hit 2.2s, like the way this continues to trade!
1 · Reply
Baskinta1
Baskinta1 Aug. 24 at 1:08 AM
$FATE One thing I would not dismiss ... FATE remains the type of small biotech that could attract a strategic buyer. Its autoimmune pipeline and off-the-shelf iPSC-derived CAR-T platform make it potentially interesting to larger pharma/cell-therapy companies. Recent biotech M&A activity also remains strong.
1 · Reply
StockDaddy68
StockDaddy68 Aug. 23 at 12:04 PM
$FATE Howdy FATE-FULL Friends I hope everyone is having a great weekend!
0 · Reply
TheeVoid
TheeVoid Aug. 22 at 1:42 PM
$FATE
1 · Reply
Rocketman808
Rocketman808 Aug. 21 at 5:00 PM
$FATE low volume games, take advantage if you are trying to add
1 · Reply
radonco
radonco Aug. 20 at 10:55 PM
$FATE this Chinese company RiboX just received IND clearance for in vivo CD19 car-t in autoimmune disease on Aug 12 from FDA and now there is a previously undisclosed death in their study being reported. https://www.cellgenetherapyreview.com/3972-News/627384-RiboX-gets-FDA-IND-clearance-for-circRNA-based-in-vivo-CAR-T-for-autoimmune-cytopenias/ https://endpoints.news/exclusive-third-death-revealed-in-chinas-popular-but-opaque-trials/
1 · Reply
StockDaddy68
StockDaddy68 Aug. 20 at 11:48 AM
$FATE Good Morning FATE-FULL Friends! Something is cooking in the kitchen!
0 · Reply
Jake140
Jake140 Aug. 20 at 10:41 AM
$FATE Morning All!!! On the move!!! Enjoy!
0 · Reply
JFDI
JFDI Aug. 19 at 11:56 PM
The same pattern that showed in bahh $MRNA is showin’ up in any $DRUG ‘s $FATE & The Return of the Desc Wedge. The Measured Move on the Desc Wedge is where the pattern originated. Yes, jus scribblin’ & dribblin’
0 · Reply
Doozio
Doozio Aug. 19 at 11:18 PM
If they ain’t 🐑 infested no moar in da $FATE of da YO then is da 🧠 spreading Roger????
1 · Reply